Insulin Glargine (Lantus) Overdose: Recognition, Emergency Response, and Prevention

Insulin glargine is a long-acting human insulin analog sold under the brand names Lantus and Basaglar (both U-100 concentration) and Toujeo (U-300 concentration). It is prescribed as a once-daily basal insulin for type 1 and type 2 diabetes. This article covers what happens when too much is taken, whether by accident or intentionally, and how that differs from an overdose of rapid-acting or short-acting insulin.

The core answer, stated plainly: an insulin glargine overdose causes hypoglycemia that can develop slowly, recur repeatedly, and last far longer than a rapid-acting insulin overdose, because glargine forms a subcutaneous depot that releases insulin over roughly 24 hours rather than peaking and clearing within a few hours. This means a person can look stable after an initial glucose correction and still develop dangerous low blood sugar many hours later. Mild, isolated excess doses are often manageable at home with repeated carbohydrate intake and vigilant monitoring; anything beyond a single extra dose at the usual amount, or any neurological symptom, warrants emergency evaluation and a monitoring period measured in a full day, not a few hours.

What is established, what is plausible, and what is not established

Established: Insulin glargine's formulation (acidic pH that precipitates at physiological pH) produces a flatter, more prolonged absorption profile than regular or rapid-acting insulin, and the FDA-approved prescribing information for Lantus describes a relatively constant concentration over roughly 24 hours. Hypoglycemia is the expected and dose-related adverse effect of any insulin overdose. The American Diabetes Association's Standards of Care define hypoglycemia thresholds (level 1: below 70 mg/dL; level 2: below 54 mg/dL; level 3: any event requiring assistance) and endorse the "Rule of 15" for treating mild-to-moderate hypoglycemia.

Plausible but not quantifiable from the sources available to this article: Exact figures such as "how many units are fatal" or "what percentage of overdoses require hospitalization" appear frequently in secondary summaries but are not something this article can state as a verified number. Case reports describing prolonged hypoglycemia after large glargine overdoses exist in the toxicology literature, but the specific figures (dose thresholds, duration of recurrence) require direct verification against the primary paper before being repeated as fact.

Not established: There is no validated dose-response curve that tells an individual patient exactly how long hypoglycemia will last after a specific excess dose. Renal function, hepatic glycogen stores, concurrent medications, and individual insulin sensitivity all change the picture, which is why generic numeric claims about "the lethal dose" are not reliable guidance for an individual.

Why insulin glargine overdose behaves differently from other insulins

Rapid-acting insulins (lispro, aspart, glulisine) and regular human insulin peak within one to a few hours and are largely cleared within four to six hours. Insulin glargine is designed to avoid a pronounced peak. After subcutaneous injection, it forms microprecipitates in the tissue that dissolve gradually, producing absorption that extends across roughly a day. This is a therapeutic feature at normal doses. In overdose, it becomes the central safety problem: the depot keeps releasing insulin long after the initial dose was given, so a patient who receives glucose and appears to recover can relapse into hypoglycemia six, twelve, or more hours later as the depot continues to empty.

This single mechanistic fact should drive every decision in this article: treat the first hypoglycemic episode, then plan for the possibility of a second, third, or fourth episode over the following day rather than assuming recovery is complete once glucose returns to normal.

Recognizing the symptoms

Hypoglycemia symptoms follow a rough gradient tied to how far glucose has fallen, though the exact glucose level at which symptoms appear varies between individuals.

Early, adrenergic symptoms (roughly glucose 55-70 mg/dL): tremor, sweating, palpitations, anxiety, hunger, and pallor. These reflect the sympathetic nervous system's counter-regulatory alarm response.

Later, neuroglycopenic symptoms (lower glucose, commonly cited around below 50 mg/dL): confusion, slurred speech, blurred vision, difficulty concentrating, unusual behavior, and poor coordination. These reflect the brain running short of its primary fuel.

Severe presentation: seizures, loss of consciousness, and coma can occur with very low or rapidly falling glucose. Any of these is a medical emergency.

An important caveat: people taking beta-blockers can have blunted adrenergic warning symptoms. The tremor, rapid heartbeat, and anxiety that normally warn of falling glucose may be muted or absent, so glucose can fall to a dangerous level with little warning. This phenomenon, sometimes discussed in the endocrinology literature as impaired hypoglycemia awareness or autonomic failure, means that people on beta-blockers who take excess glargine need more frequent glucose checks, not less, because they cannot rely on how they feel.

Immediate response for a conscious person: the Rule of 15

For someone who is conscious, able to swallow safely, and whose glucose is low but above roughly 54 mg/dL, the standard first step is oral fast-acting carbohydrate: 15 grams, then recheck glucose in 15 minutes, and repeat if still below 70 mg/dL. Reasonable sources of 15 grams include glucose tablets, four ounces of fruit juice, or a tablespoon of sugar in water. Fatty foods like chocolate or peanut butter crackers are not appropriate first choices because fat slows gastric emptying and delays the glucose rise.

Because of the depot effect described above, a single correction is not the end of the process for a glargine overdose. After the initial correction:

1. Eat a meal with complex carbohydrate and protein within about 30 minutes.
2. Recheck blood glucose every 30 to 60 minutes for the next 12 to 24 hours.
3. Keep fast-acting glucose and a glucagon kit within reach.
4. Do not go to sleep without a monitoring plan: either a person checking on the patient periodically through the night, or a continuous glucose monitor with a low-glucose alarm.

If the dose taken clearly exceeds the prescribed amount by a large margin, or if there is real uncertainty about how much was injected, calling Poison Control (1-800-222-1222 in the United States) or going to an emergency department is the safer choice rather than waiting to see what happens.

Decision framework: matching the response to the size of the error

Not every excess dose needs the same response. The table below is a general decision aid built from the pharmacokinetic reasoning above and standard hypoglycemia management principles; it does not replace individualized medical advice, and any uncertainty should be resolved by calling Poison Control or going to an emergency department.

The row that most often gets skipped in practice is the monitoring commitment. Because the depot can keep releasing insulin for a day or more, a technically "mild" overdose that is not followed by real monitoring for the full 24-hour window is not actually a low-risk situation.

Emergency department and inpatient management

When a significant glargine overdose reaches a hospital, management centers on sustained glucose correction and extended observation, not a single treatment.

IV dextrose is the mainstay. An initial bolus restores glucose within minutes, and a continuous dextrose infusion is typically needed afterward because the subcutaneous depot keeps releasing insulin. The infusion is titrated against repeated glucose checks rather than given as a one-time fix.

Glucagon (1 mg intramuscular or subcutaneous, or intranasal glucagon such as Baqsimi, which the FDA approved in 2019 as a needle-free option for severe hypoglycemia) can bridge the gap before IV access is established or serve as an adjunct. Glucagon raises glucose by triggering the liver to release stored glycogen, so its effect is temporary (roughly an hour or so) and depends on adequate liver glycogen. It is likely to be less effective in people who are malnourished, have chronic heavy alcohol use, or have been fasting.

Extended monitoring is where glargine overdose management differs most from rapid-acting insulin overdose. Because the depot can continue releasing insulin well beyond the first several hours, a minimum observation period on the order of 24 hours with frequent glucose checks is standard practice for any clinically significant glargine overdose. Some published case reports describe recurrent hypoglycemia occurring many hours after the original dose in patients who initially looked stable, though exact timing figures from those reports should be verified against the primary literature before being treated as a fixed rule for a given patient.

Potassium monitoring matters because insulin drives potassium into cells; a large overdose can produce hypokalemia, which raises the risk of cardiac arrhythmia. Serum potassium is typically checked on arrival and rechecked periodically during the monitoring period.

Severe, intensive-care-level insulin overdoses are managed within general critical care frameworks for toxin-induced refractory hypoglycemia, an area covered in the broader intensive and emergency medicine literature; a specific overdose protocol should be verified against a primary source rather than assumed from this summary (see the 2016 International Symposium on Intensive Care and Emergency Medicine abstract collection, which addresses critical care management topics of this kind, in the references below) [1].

Accidental excess dose: common causes

Accidental basal insulin overdoses tend to follow a handful of recognizable patterns rather than being random:

• Basal-bolus mix-up. Injecting glargine from the wrong pen when a rapid-acting dose was intended, or vice versa. Pens that look similar and are stored together increase this risk.
• Dose doubling. Not remembering whether the evening dose was already taken and injecting again. This is a particular risk for older adults or anyone managing insulin without a tracking system.
• Concentration confusion. Switching between U-100 (Lantus, Basaglar) and U-300 (Toujeo) without adjusting for the fact that one milliliter of U-300 contains three times the insulin of one milliliter of U-100. Doses are not interchangeable unit-for-unit by volume.
• Pediatric exposure. A child gaining access to an insulin pen left within reach.

For a single accidental double dose at the patient's usual prescribed amount, home management with frequent glucose checks over the following day is often reasonable, provided a capable adult is available and the person can eat and drink safely. For larger errors, especially anything reaching or exceeding roughly three times the prescribed dose, or a substantial dose in someone who does not normally take insulin, emergency evaluation is warranted even if the initial glucose reading looks acceptable, because the depot effect means the worst of it may not have arrived yet.

Prevention: what actually reduces these errors

Patient education alone tends to underperform system-level changes:

• Physical separation of basal and bolus pens, stored in different locations with clearly different labeling, reduces mix-up risk.
• Connected insulin pens that log the time and amount of each injection directly address the "did I already take it?" problem that drives dose doubling.
• Continuous glucose monitors with low-glucose alarms provide an early warning before symptoms appear, which matters most for people whose hypoglycemia awareness is blunted.
• Explicit counseling on concentration switches. Anyone moving between U-100 and U-300 glargine needs a clear conversation about the fact that doses are not interchangeable by volume. The FDA has specifically warned against transferring insulin from a prefilled pen into a syringe, which is a separate but related source of serious dosing errors.
• A current glucagon kit in the home, with the expiration date checked periodically. Intranasal glucagon (Baqsimi) requires no reconstitution and can be given by a family member with minimal training; injectable glucagon kits remain a standard alternative.

Special populations

Older adults often have blunted counter-regulatory hormone responses and reduced awareness of early hypoglycemia symptoms, which is part of why the ADA's Standards of Care allow a less stringent glycemic target for older adults with multiple comorbidities. The threshold for emergency evaluation after an accidental excess dose should be lower in this group.

People with significant chronic kidney disease clear insulin more slowly because the kidneys handle a meaningful share of insulin clearance. Reduced renal clearance can prolong the hypoglycemic effect of any insulin dose, including glargine, and case literature describes unusually prolonged recurrent hypoglycemia in advanced kidney disease after insulin overdose, though exact durations should be verified against the primary report rather than treated as a fixed number.

People with liver disease have reduced glycogen stores, which makes glucagon less effective and makes exogenous glucose more important for recovery.

People taking sulfonylureas or meglitinides alongside glargine face a combined risk: the exogenous insulin overdose plus drug-stimulated endogenous insulin secretion, which can make hypoglycemia more refractory to a single round of treatment.

When to call 911 versus go to the ER versus manage at home

Call 911 immediately if: the person is unconscious, seizing, or unable to swallow safely; blood glucose is very low and not responding to oral glucose within about 15 minutes; the person is alone and becoming confused; or the dose taken is a large multiple of the prescribed amount.

Go to the emergency department if: glucose has dropped below roughly 54 mg/dL on two consecutive checks despite oral carbohydrate; the person is on a beta-blocker and cannot reliably sense hypoglycemia; kidney function is significantly impaired; or the wrong concentration (U-300 instead of U-100, or the reverse) was used and the actual unit dose taken is uncertain.

Home management with close monitoring may be reasonable if: the excess was a single additional dose at the usual prescribed amount, glucose is above 70 mg/dL after initial carbohydrate intake, a capable adult can check glucose every one to two hours for the next 24 hours, and a glucagon kit is on hand.

Poison Control (1-800-222-1II22, or 1-800-222-1222) is available around the clock in the United States and can help decide, over the phone, whether a specific situation needs emergency transport or can be managed at home with monitoring.